Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cordis Counters TAXUS IV With “New SIRIUS,” Critiques Angiographic Data

This article was originally published in The Gray Sheet

Executive Summary

The revascularization rates associated with Boston Scientific's Taxus paclitaxel-eluting stent in TAXUS IV are "artificially" depressed by the relatively low rate of angiographic follow-up in the trial, according to rival Johnson & Johnson/Cordis

You may also be interested in...



Cypher, Taxus Perform Equally Well In Trials, Registries – Meier Analysis

The overall clinical performance of Boston Scientific's Taxus and J&J/Cordis' Cypher drug-eluting coronary stents is practically equivalent, according to Bernard Meier, MD, University Hospital, Bern, Switzerland

Cypher, Taxus Perform Equally Well In Trials, Registries – Meier Analysis

The overall clinical performance of Boston Scientific's Taxus and J&J/Cordis' Cypher drug-eluting coronary stents is practically equivalent, according to Bernard Meier, MD, University Hospital, Bern, Switzerland

DES Study Results Provoke SIRIUS Flurry Of Correspondence

Drug-eluting stents should be compared with off-pump coronary bypass surgery in a randomized trial for patients with high-risk lesions, according to Johnson & Johnson (Cypher) SIRIUS study lead investigators

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel